Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

A survey of 1700 Americans 45 and older found that 79% would want to know if they were in the early stages of Alzheimer's.

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease.

The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

At that level, both lecanemab and donanemab act very similarly. "Further work is needed to understand what is most important: binding oligomeric structures or binding amyloid plaques. This is ...

“While we don’t know whether donanemab or lecanemab can arrest Alzheimer’s, they do appear to help people with mild cognitive impairment and extend the time they are independent and able to ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month. Between his ...